• 1
    Falk GW. Barrett's esophagus. Gastroenterology 2002; 122: 156991.
  • 2
    Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002; 346: 83642.
  • 3
    Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults – update 2004. Can J Gastroenterol 2005; 19: 1535.
  • 4
    Veldhuyzen van Zanten SJO, Bradette M, Chiba N, et al. Evidence based recommendations for short and long-term management of uninvestigated dyspepsia in primary care – an update of the CanDys clinical management tool. Can J Gastroenterol 2005; 19: 285303.
  • 5
    Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 4617.
  • 6
    Thomson ABR, Barkun AN, Armstrong D, et al. The prevalence of clinically significant upper gastrointestinal findings in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment – Prompt Endoscopy (CADET-PE) Study. Aliment Pharm Ther 2003; 17: 148191.
  • 7
    Veldhuyzen van Zanten SJO, Flook N, Chiba N, et al. An evidence-based approach to the management of patients with dyspepsia in the era of Helicobacter pylori. CMAJ 2000; 162 (Suppl. 12): S323.
  • 8
    Spechler SJ. Intestinal metaplasia at the gastroesophageal junction. Gastroenterology 2004; 126: 56775.
  • 9
    Veldhuyzen van Zanten SJO, Hydra A. Assessing observer variation using kappa. Netherlands J Med (Nederlands Tijdschrift van Geneeskunde) 1988; 132: 199202.
  • 10
    Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 31030.
  • 11
    Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997; 26: 48794.
  • 12
    Breslin NP, Thomson AB, Bailey RJ, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000; 46: 937.
  • 13
    Meining A, Ott R, Becker I, et al. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only – what is the clinical significance? Gut 2004; 53: 14027.
  • 14
    Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997; 92: 12937.
  • 15
    Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002; 47: 25664.
  • 16
    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 82531.
  • 17
    Devesa SS, Blot WJ, Fraumeni Jr JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 204953.
  • 18
    National Cancer Institute of Canada: Canadian Cancer Statistics 2002. Toronto, Canada: National Cancer Institute of Canada, 2002.
  • 19
    Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 3338.
  • 20
    Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer: scientific review. JAMA 2002; 287: 197281.
  • 21
    Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JHP. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001; 13: 63945.
  • 22
    Macdonald CE, Wicks AC, Playford RJ. Final results from 10-year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321: 12525.
  • 23
    Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 17686.
  • 24
    Sharma P, Sidorenko EI. Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut 2005; 54 (Suppl. 1): i2732.
  • 25
    Peters J, Clark G, Ireland A, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 81321.
  • 26
    van Sandick J, van Lanschot J, Kuiken B, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 21622.
  • 27
    Bytzer P, Christensen P, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 8691.
    Direct Link:
  • 28
    MacNeil-Covin L, Casson A, Malatjalian D, Veldhuyzen van Zanten SJO. A survey of Canadian gastroenterologists about the management of Barrett's esophagus. Can J Gastroenterol 2003; 17: 3137.
  • 29
    Rose C, Leddin D, Veldhuyzen van Zanten SJO. Diminishing returns: modeling the future proportion of gastroscopies required for surveillance of patient's diagnosed with Barrett esophagus (BE) using existing guidelines. Gastroenterology 2005; 128 (Suppl. 2): A-240.